313 related articles for article (PubMed ID: 25732040)
1. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Favero F; McGranahan N; Salm M; Birkbak NJ; Sanborn JZ; Benz SC; Becq J; Peden JF; Kingsbury Z; Grocok RJ; Humphray S; Bentley D; Spencer-Dene B; Gutteridge A; Brada M; Roger S; Dietrich PY; Forshew T; Gerlinger M; Rowan A; Stamp G; Eklund AC; Szallasi Z; Swanton C
Ann Oncol; 2015 May; 26(5):880-887. PubMed ID: 25732040
[TBL] [Abstract][Full Text] [Related]
2. Clonal evolution of glioblastoma under therapy.
Wang J; Cazzato E; Ladewig E; Frattini V; Rosenbloom DI; Zairis S; Abate F; Liu Z; Elliott O; Shin YJ; Lee JK; Lee IH; Park WY; Eoli M; Blumberg AJ; Lasorella A; Nam DH; Finocchiaro G; Iavarone A; Rabadan R
Nat Genet; 2016 Jul; 48(7):768-76. PubMed ID: 27270107
[TBL] [Abstract][Full Text] [Related]
3. Molecular Evolution of
Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
[TBL] [Abstract][Full Text] [Related]
4. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
[TBL] [Abstract][Full Text] [Related]
5. IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Yamaguchi S; Tanino M; Murata J; Houkin K
Brain Tumor Pathol; 2013 Apr; 30(2):67-72. PubMed ID: 22752663
[TBL] [Abstract][Full Text] [Related]
6. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Tran AN; Lai A; Li S; Pope WB; Teixeira S; Harris RJ; Woodworth DC; Nghiemphu PL; Cloughesy TF; Ellingson BM
Neuro Oncol; 2014 Mar; 16(3):414-20. PubMed ID: 24305712
[TBL] [Abstract][Full Text] [Related]
7. Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Kim J; Lee IH; Cho HJ; Park CK; Jung YS; Kim Y; Nam SH; Kim BS; Johnson MD; Kong DS; Seol HJ; Lee JI; Joo KM; Yoon Y; Park WY; Lee J; Park PJ; Nam DH
Cancer Cell; 2015 Sep; 28(3):318-28. PubMed ID: 26373279
[TBL] [Abstract][Full Text] [Related]
8. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
9. Copy Number Profiling of Brazilian Astrocytomas.
Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
[TBL] [Abstract][Full Text] [Related]
10. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
11. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
[TBL] [Abstract][Full Text] [Related]
12. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
13. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma.
Phillips JJ; Aranda D; Ellison DW; Judkins AR; Croul SE; Brat DJ; Ligon KL; Horbinski C; Venneti S; Zadeh G; Santi M; Zhou S; Appin CL; Sioletic S; Sullivan LM; Martinez-Lage M; Robinson AE; Yong WH; Cloughesy T; Lai A; Phillips HS; Marshall R; Mueller S; Haas-Kogan DA; Molinaro AM; Perry A
Brain Pathol; 2013 Sep; 23(5):565-73. PubMed ID: 23438035
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Glioblastoma.
Nam JY; de Groot JF
J Oncol Pract; 2017 Oct; 13(10):629-638. PubMed ID: 29020535
[TBL] [Abstract][Full Text] [Related]
15. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
[TBL] [Abstract][Full Text] [Related]
16. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.
Burford A; Little SE; Jury A; Popov S; Laxton R; Doey L; Al-Sarraj S; Jürgensmeier JM; Jones C
PLoS One; 2013; 8(8):e71777. PubMed ID: 23990986
[TBL] [Abstract][Full Text] [Related]
17. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Sturm D; Witt H; Hovestadt V; Khuong-Quang DA; Jones DT; Konermann C; Pfaff E; Tönjes M; Sill M; Bender S; Kool M; Zapatka M; Becker N; Zucknick M; Hielscher T; Liu XY; Fontebasso AM; Ryzhova M; Albrecht S; Jacob K; Wolter M; Ebinger M; Schuhmann MU; van Meter T; Frühwald MC; Hauch H; Pekrun A; Radlwimmer B; Niehues T; von Komorowski G; Dürken M; Kulozik AE; Madden J; Donson A; Foreman NK; Drissi R; Fouladi M; Scheurlen W; von Deimling A; Monoranu C; Roggendorf W; Herold-Mende C; Unterberg A; Kramm CM; Felsberg J; Hartmann C; Wiestler B; Wick W; Milde T; Witt O; Lindroth AM; Schwartzentruber J; Faury D; Fleming A; Zakrzewska M; Liberski PP; Zakrzewski K; Hauser P; Garami M; Klekner A; Bognar L; Morrissy S; Cavalli F; Taylor MD; van Sluis P; Koster J; Versteeg R; Volckmann R; Mikkelsen T; Aldape K; Reifenberger G; Collins VP; Majewski J; Korshunov A; Lichter P; Plass C; Jabado N; Pfister SM
Cancer Cell; 2012 Oct; 22(4):425-37. PubMed ID: 23079654
[TBL] [Abstract][Full Text] [Related]
18. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
Corless CL; Ballman KV; Antonescu CR; Kolesnikova V; Maki RG; Pisters PW; Blackstein ME; Blanke CD; Demetri GD; Heinrich MC; von Mehren M; Patel S; McCarter MD; Owzar K; DeMatteo RP
J Clin Oncol; 2014 May; 32(15):1563-70. PubMed ID: 24638003
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Tabouret E; Tchoghandjian A; Denicolai E; Delfino C; Metellus P; Graillon T; Boucard C; Nanni I; Padovani L; Ouafik L; Figarella-Branger D; Chinot O
Oncotarget; 2015 May; 6(13):11664-75. PubMed ID: 25860928
[TBL] [Abstract][Full Text] [Related]
20. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Ohno M; Narita Y; Miyakita Y; Matsushita Y; Arita H; Yonezawa M; Yoshida A; Fukushima S; Takami H; Ichimura K; Shibui S
Jpn J Clin Oncol; 2016 Jan; 46(1):31-9. PubMed ID: 26603354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
